Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In episode 2 of an ongoing series of sharing sessions between a physician and patient, Robert Gish, MD, FAASLD, and patient advocate, Alan Wang, discuss stigma as a barrier to optimal HBV care and treatment. The conversation focuses on how stigma affected Alan’s engagement with his care and strategies to overcome stigma as a barrier to HBV care.
Professor of Medicine
Loma Linda University
Loma Linda, California
Hepatitis B Foundation
This program has been made available online.
Brief Clinical Care Options (CCO) presentation on APASL guidance on limitations of current HCC surveillance recommendations in chronic HBV infection
Takeshi Saito, MD, PhD, discusses the limitations of current approaches to treating HDV and looks ahead to new and emerging HDV therapies, from Clinical Care Options (CCO)
Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.
Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.